Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

H.C. Wainwright maintained a positive stance on Arcturus Therapeutics (NASDAQ:ARCT) shares, reiterating a Buy rating and a price target of $63. Currently trading at $16.97, the stock has significant ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...

Oil and gas companies Arcturus Corp. and Aschere Energy LLC, along with founder Leon Ali Parvizian, must pay more than $10 ...

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

In the assessment of 12-month price targets, analysts unveil insights for Arcturus Therapeutics, presenting an average target ...

BTIG initiated coverage of Arcturus Therapeutics (ARCT) with a Buy rating and $41 price target Arcturus is a commercial-stage biotechnology ...

周一，H.C. Wainwright对Arcturus Therapeutics股票保持积极态度，重申买入评级，目标价为63美元。根据 InvestingPro 数据，该股目前交易价为16.97美元，分析师目标价区间为41美元至140美元，显示出巨大的上涨潜力。该公司的认可紧随明治制药（Meiji Seika ...

Skyven Technologies, a leader in emissions-free industrial steam, and Kyotherm, a renowned financier of renewable thermal ...

周二，BTIG分析师开始对Arcturus Therapeutics (NASDAQ: ARCT )进行覆盖，给予"买入"评级，并设定41.00美元的目标价。该商业化阶段的生物技术公司以mRNA疗法和疫苗为重点，目前交易价格为16.49美元，市值4.47亿美元。根据 InvestingPro ...

BTIG Research began coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) in a research report issued on Tuesday, MarketBeat reports. The brokerage set a “buy” rating and a ...